机构:[1]Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China[2]Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai 200092, China[3]Department of Biliary- Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China[4]State Key Laboratory for Oncogenes and Related Genes, Shanghai 200127, China[5]Department of General Surgery, Shanxi Provincial Cancer Hospital, Taiyuan 030013, Shanxi Province, China[6]Department of GI Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China吉林大学中日联谊医院[7]Department of Gastrointestinal and Hernia Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650031, Yunnan Province, China昆明医科大学附属第一医院[8]Department of Hepatobiliary Surgery, Nantong Tumor Hospital, Nantong 226361, Jiangsu Province, China[9]Department of General Surgery, Taizhou Municipal Hospital, Taizhou 318000, Jiangsu Province, China[10]Department of Hepatobiliary Surgery, Wuxi Second People's Hospital, Wuxi 214002, Jiangsu Province, China[11]Department of General Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, Zhejiang Province, China[12]Department of Biliary Tract Surgery, Second Military Medical University, Secondary Military Medical University, Shanghai 200438, China[13]Department of General Surgery, Changshu No. 1 People’s Hospital Affiliated to Soochow University, Changshu 215500, Jiangsu Province, China[14]Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin 150086, Heilongjiang Province, China[15]Department of General Surgery, Shaoxing Second Hospital, Shaoxing 312000, Zhejiang Province, China[16]Department of HPB Surgery, Changzhou No. 2 People’s Hospital, Changzhou 213003, Jiangsu Province, China[17]Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150009, Heilongjiang Province, China[18]Department of Hepatobiliary Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China中国医科大学附属盛京医院[19]Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330019, Jiangxi Province, China[20]Department of HPB Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266003, Shandong Province, China[21]Department of General Surgery, Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 202150, China[22]Department of Hepatobiliary Surgery, People's Hospital of Hunan Province, Changsha 410001, Hunan Province, China[23]Department of HPB Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China[24]Department of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong Province, China[25]Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China[26]Department of GI Surgery, The First People's Hospital of Taicang, Taicang 215400, Jiangsu Province, China[27]Department of General Surgery, Henan Cancer Hospital, Zhengzhou 450003, Henan Province, China河南省肿瘤医院[28]Clinical Research Unit, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China[29]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China[30]Department of Liver Surgery, Chinese Univ Hong Kong, Prince Wales Hosp, Shatin, Hong Kong, China
BACKGROUND Whether regional lymphadenectomy (RL) should be routinely performed in patients with T1b gallbladder cancer (GBC) remains a subject of debate. AIM To investigate whether RL can improve the prognosis of patients with T1b GBC. METHODS We studied a multicenter cohort of patients with T1b GBC who underwent surgery between 2008 and 2016 at 24 hospitals in 13 provinces in China. The log-rank test and Cox proportional hazards model were used to compare the overall survival (OS) of patients who underwent cholecystectomy (Ch) + RL and those who underwent Ch only. To investigate whether combined hepatectomy (Hep) improved OS in T1b patients, we studied patients who underwent Ch + RL to compare the OS of patients who underwent combined Hep and patients who did not. RESULTS Of the 121 patients (aged 61.9 +/- 10.1 years), 77 (63.6%) underwent Ch + RL, and 44 (36.4%) underwent Ch only. Seven (9.1%) patients in the Ch + RL group had lymph node metastasis. The 5-year OS rate was significantly higher in the Ch + RL group than in the Ch group (76.3% vs 56.8%, P = 0.036). Multivariate analysis showed that Ch + RL was significantly associated with improved OS (hazard ratio: 0.51; 95% confidence interval: 0.26-0.99). Among the 77 patients who underwent Ch + RL, no survival improvement was found in patients who underwent combined Hep (5-year OS rate: 79.5% for combined Hep and 76.1% for no Hep; P = 0.50). CONCLUSION T1b GBC patients who underwent Ch + RL had a better prognosis than those who underwent Ch. Hep + Ch showed no improvement in prognosis in T1b GBC patients. Although recommended by both the National Comprehensive Cancer Network and Chinese Medical Association guidelines, RL was only performed in 63.6% of T1b GBC patients. Routine Ch + RL should be advised in T1b GBC. (c) The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
基金:
National Natural
Science Foundation of China
(General Program), No.
31620103910; National Natural
Science Foundation of China (Key
Program), No. 81874181; National
Health Commission of China, No.
2019ZX09301158; Shanghai
Municipal Commission of
Economy and Informatization, No.
2019RGZN01096; Shanghai
Shenkang Hospital Development
Center, No. 12018107; and Xinhua
Hospital Affiliated to Shanghai Jiao
Tong University School of
Medicine, No. 19XHCR13D.
第一作者机构:[1]Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China[2]Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai 200092, China
共同第一作者:
通讯作者:
通讯机构:[2]Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai 200092, China[3]Department of Biliary- Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China[4]State Key Laboratory for Oncogenes and Related Genes, Shanghai 200127, China[*1]Shanghai Key Laboratory of Biliary Tract Disease Research, No. 1665 Kongjiang Road, Yangpu District, Shanghai 200092, China.
推荐引用方式(GB/T 7714):
Ren Tai,Li Yong-Sheng,Dang Xue-Yi,et al.Prognostic significance of regional lymphadenectomy in T1b gallbladder cancer: Results from 24 hospitals in China[J].WORLD JOURNAL OF GASTROINTESTINAL SURGERY.2021,13(2):176-186.doi:10.4240/wjgs.v13.i2.176.
APA:
Ren, Tai,Li, Yong-Sheng,Dang, Xue-Yi,Li, Yang,Shao, Zi-Yu...&Liu, Ying-Bin.(2021).Prognostic significance of regional lymphadenectomy in T1b gallbladder cancer: Results from 24 hospitals in China.WORLD JOURNAL OF GASTROINTESTINAL SURGERY,13,(2)
MLA:
Ren, Tai,et al."Prognostic significance of regional lymphadenectomy in T1b gallbladder cancer: Results from 24 hospitals in China".WORLD JOURNAL OF GASTROINTESTINAL SURGERY 13..2(2021):176-186